FAQs

The 5th Nasal Formulation & Delivery Summit is the industry's only dedicated forum focused exclusively on advancing intranasal drug development.

Bringing together biotech, pharma, device developers, formulation experts, clinicians, and regulatory leaders, the summit is designed to help overcome the key scientific, translational, regulatory, and commercial challenges limiting the development of successful nasal therapies.

Attendees will explore topics including nose-to-brain delivery, clinical translation, formulation development, device selection, regulatory strategy, drug-device compatibility, biologics, peptides, vaccines, RNA therapeutics, and commercialization.

Download the Full Event Guide here to learn more about what's on offer.

This summit has been designed for professionals involved in the research, development, formulation, manufacture, regulation, and commercialization of intranasal products.

Relevant job functions include:

• Research & Development
• Drug Development
• Translational Science
• Clinical Development
• Formulation Development
• Pharmaceutical Sciences
• Drug Delivery
• CMC
• Regulatory Affairs
• Medical Affairs
• Business Development
• Strategic Partnerships

Typical attendees include:

• CEOs
• CSOs
• CMOs
• Heads of R&D
• Directors of Drug Development
• Formulation Scientists
• Clinical Development Leaders
• Regulatory Specialists
• Device Development Experts

Yes.

While nose-to-brain delivery remains an important theme throughout the program, the summit covers a broad range of intranasal development topics including:

• Vaccines
• Infectious diseases
• Biologics
• Peptides
• RNA therapeutics
• Emergency-use products
• Drug-device combination products
• Powder formulations
• Regulatory strategy
• Commercialization planning

If your organization is developing any intranasal therapy, there will be relevant content throughout the program. Learn more here.

Absolutely.

Many attendees join the summit while evaluating delivery strategies, assessing translational pathways, selecting device technologies, or building development plans.

The program includes multiple discussions focused on reducing development risk, improving clinical translation, and understanding what evidence regulators, investors, and partners expect to see before supporting intranasal programs.

Explore why you should attend here.